Drug Detail

Information about Venclexta

Generic Name	Venetoxlax
IND
Brand Name (US)	Venclexta
Manufacturer	Abbvie / Genetech
Drug Type
Delivery	Oral
Approval Status	Approved for a non-GIST application
Indications	CLL | SLL and AML
Overall Strategy
Strategy	Unblock cell death genes
Drug Category	BCL-2 inhibitor

Venclexta (venetoclax) is an inhibitor of Bcl-2, a protein involved in triggering apoptosis (a type of cell death). It is approved for chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and for acute myeloid leukemia (AML).